Insilico Medicine

IPO

Generative AI and Automation for Longevity and Sustainability

Public · Hong Kong, Hong Kong · Founded 2014 · $632.8M raised

Headquarters
Hong Kong
Employees
201–500
Founded
2014
Business Model
B2B
Total Funding
$632.8M
Last Round
$123.0M Series EMar 2026
Rounds
9
Type
Public

About

Insilico Medicine develops breakthrough solutions using generative artificial intelligence to accelerate drug discovery and development for diseases like cancer, fibrosis, immunity, and CNS disorders. The company aims to extend healthy productive longevity by reducing time and cost in bringing life-saving medications to patients. Platforms include Chemistry42, Biology42, and Pharma.ai.

Summary

Insilico Medicine is an Artificial Intelligence company based in Hong Kong, Hong Kong, founded in 2014. It has raised $632.8M in total across 9 rounds, most recently a $123.0M Series E round in Mar 2026. Investors include Warburg Pincus, OrbiMed and F-Prime Capital.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series ESeries EMar 2026
$123.0M

Sign up to see all 10 rounds

Series A through Series E — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Insilico Medicine on Indexed.vc
<a href="https://indexed.vc/companies/insilico-medicine"><img src="https://indexed.vc/api/badge/company/insilico-medicine" alt="Insilico Medicine on Indexed.vc" width="260" height="76" /></a>